Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 15

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 15
---
” refer to privately held Mosaic ImmunoEngineering, Inc. prior to the completion of the Reverse Merger.

Risks Related
to Our Operations 

While the Company’s financial statements
have been prepared on a going concern basis, we do not currently have sufficient working capital to fund our existing liabilities or any
planned operations for the next twelve months and we may be required to cease our operations altogether if we are unable to secure sufficient
funding. 

There is substantial doubt about our ability to continue
as a going concern, as we currently do not have adequate financial resources to fund our existing liabilities or potential future operations
for at least twelve months from the filing of this Report. As of December 31, 2024, the Company had incurred operating losses since inception,
and continues to generate losses from operations, and has cash and equivalents of $115,019, an accumulated deficit of $8,838,320 and current
liabilities of $5,537,270. As a result, our existing cash resources are not sufficient to meet our anticipated needs over the next twelve
months from the date hereof and we would need to raise additional capital to continue our operations and to implement our business plan,
which capital is unlikely to be available on favorable terms or at all. These matters raise substantial doubt about the Company’s
ability to continue as a going concern.

If we raise funds from the issuance of equity securities
(which will be challenging in light of current market conditions combined with our limited technologies), substantial dilution to our
existing stockholders would likely result. If we raise additional funds by incurring debt financing (also challenging in light of current
market conditions combined with our limited technologies), the terms of the debt may involve significant cash payment obligations as well
as covenants and specific financial ratios that may restrict our ability to operate our business. Since the closing date of the Reverse
Merger, our limited cash position has required us to perform only limited development activities and to delay and scale back our development
programs and other activities to remain afloat. If we continue to have insufficient funds, we may be required to cease our operations
altogether.

Our ability to pursue the research and development
activities and other initiatives discussed in the following risk factors and elsewhere in this Report is pending our ability to raise
sufficient capital and successfully identify new product candidates and license or acquire those rights, which may not be available to
us in light of current market conditions combined with our limited technologies.

The consolidated financial statements included in